DYAI - Dyadic International Inc Stock Price, Fair Value and News

$1.91+0.24 (+14.37%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

DYAI Price Action

Last 7 days

69.0%

Last 30 days

73.6%

Last 90 days

31.7%

Trailing 12 Months

5.0%

DYAI RSI Chart

DYAI Valuation

Market Cap

56.5M

Price/Earnings (Trailing)

-8.93

Price/Sales (Trailing)

27.02

Price/Free Cashflow

-13.45

DYAI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

DYAI Fundamentals

DYAI Revenue

Revenue (TTM)

1.1M

Rev. Growth (Yr)

393%

Rev. Growth (Qtr)

407.26%

DYAI Earnings

Earnings (TTM)

-6.3M

Earnings Growth (Yr)

87.4%

Earnings Growth (Qtr)

90.05%

DYAI Profitability

Return on Equity

-185.52%

Return on Assets

-58.58%

Free Cashflow Yield

-7.43%

DYAI Investor Care

Shares Dilution (1Y)

2.70%

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	3.3M	3.4M	3.0M	1.1M
2022	2.6M	2.3M	2.5M	2.9M
2021	0	2.2M	2.4M	2.3M
2020	1.6M	1.7M	1.7M	1.6M
2019	1.5M	1.7M	1.9M	1.7M
2018	892.7K	1.0M	1.2M	1.3M
2017	0	0	0	758.4K

Get all data in R, Python etc through our Historical Stock Data APIs

About Dyadic International Inc

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles, protein antigens, ferritin nanoparticles, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to demonstrate the safety in humans of a protein produced from C1-cell protein production platform. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; and strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., as well as co-development and marketing agreement with Fermbox Bio Inc to design, Develop, and commercialize animal free alternative proteins and biomaterials The company was founded in 1979 and is headquartered in Jupiter, Florida.

CEO	Mr. Mark A. Emalfarb
WEBSITE	dyadic.com
SECTOR	Healthcare
INDUSTRY	Biotechnology

Dyadic International Inc Frequently Asked Questions

What is the ticker symbol for Dyadic International Inc? What does DYAI stand for in stocks?

DYAI is the stock ticker symbol of Dyadic International Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Dyadic International Inc (DYAI)?

As of Fri Nov 22 2024, market cap of Dyadic International Inc is 56.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DYAI stock?

You can check DYAI's fair value in chart for subscribers.

Is Dyadic International Inc a good stock to buy?

The fair value guage provides a quick view whether DYAI is over valued or under valued. Whether Dyadic International Inc is cheap or expensive depends on the assumptions which impact Dyadic International Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DYAI.

What is Dyadic International Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Nov 22 2024, DYAI's PE ratio (Price to Earnings) is -8.93 and Price to Sales (PS) ratio is 27.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DYAI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Dyadic International Inc's stock?

In the past 10 years, Dyadic International Inc has provided 0.038 (multiply by 100 for percentage) rate of return.